BRPI0514731A - derivados de pirimidina - Google Patents

derivados de pirimidina

Info

Publication number
BRPI0514731A
BRPI0514731A BRPI0514731-0A BRPI0514731A BRPI0514731A BR PI0514731 A BRPI0514731 A BR PI0514731A BR PI0514731 A BRPI0514731 A BR PI0514731A BR PI0514731 A BRPI0514731 A BR PI0514731A
Authority
BR
Brazil
Prior art keywords
pyrimidine derivatives
pharmaceuticals
processes
formula
production
Prior art date
Application number
BRPI0514731-0A
Other languages
English (en)
Inventor
Eiji Kawahara
Takahiro Miyake
Johannes Roesel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0514731A publication Critical patent/BRPI0514731A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

DERIVADOS DE PIRIMIDINA A presente invenção refere-se a novos derivados de pirimidina de fórmula (I) processos para sua produção, seu uso como farmacêuticos, e composições farmacêuticas compreendendo-os.
BRPI0514731-0A 2004-08-27 2005-08-26 derivados de pirimidina BRPI0514731A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419160.7A GB0419160D0 (en) 2004-08-27 2004-08-27 Organic compounds
PCT/EP2005/009255 WO2006021457A2 (en) 2004-08-27 2005-08-26 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0514731A true BRPI0514731A (pt) 2008-06-24

Family

ID=33104745

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514731-0A BRPI0514731A (pt) 2004-08-27 2005-08-26 derivados de pirimidina

Country Status (24)

Country Link
US (1) US7910585B2 (pt)
EP (1) EP1784399B1 (pt)
JP (1) JP4674236B2 (pt)
KR (1) KR100894349B1 (pt)
CN (1) CN101006079A (pt)
AR (1) AR050536A1 (pt)
AT (1) ATE512960T1 (pt)
AU (1) AU2005276585B2 (pt)
BR (1) BRPI0514731A (pt)
CA (1) CA2575720C (pt)
EC (1) ECSP077259A (pt)
ES (1) ES2366038T3 (pt)
GB (1) GB0419160D0 (pt)
GT (1) GT200500229A (pt)
IL (1) IL181386A0 (pt)
MA (1) MA28813B1 (pt)
NO (1) NO20071504L (pt)
PE (1) PE20060504A1 (pt)
PL (1) PL1784399T3 (pt)
PT (1) PT1784399E (pt)
RU (1) RU2395507C2 (pt)
TN (1) TNSN07074A1 (pt)
TW (1) TW200621728A (pt)
WO (1) WO2006021457A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP2447359B1 (en) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8148391B2 (en) * 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
BRPI0722384A2 (pt) 2006-12-08 2012-06-12 Irm Llc compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
EP2112880A4 (en) * 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYL-BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSING METHODS
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
BRPI0914927B8 (pt) 2008-06-17 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN101935317B (zh) * 2009-07-01 2013-08-28 上海药明康德新药开发有限公司 2-甲基-7-(取代嘧啶-4-氨基)-4-(取代哌啶-1-基)异吲哚啉-1-酮及中间体的合成方法
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PL2646448T3 (pl) * 2010-11-29 2017-12-29 OSI Pharmaceuticals, LLC Makrocykliczne inhibitory kinazy
ES2691673T3 (es) 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2975403B1 (en) 2013-02-13 2018-05-02 Hirotomo Shibaguchi Rapid allergy testing method
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
KR20220105631A (ko) * 2019-09-13 2022-07-27 님버스 새턴 인코포레이티드 Hpk1 길항제 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6776480B2 (en) 2001-07-18 2004-08-17 Sola International Holdings, Ltd. Spectacle frames for shaped lenses defined by monoformal carrier surfaces
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2006021457A2 (en) 2006-03-02
AU2005276585B2 (en) 2009-07-30
AU2005276585A1 (en) 2006-03-02
ECSP077259A (es) 2007-03-29
RU2007110946A (ru) 2008-10-10
WO2006021457A3 (en) 2006-07-13
GB0419160D0 (en) 2004-09-29
KR100894349B1 (ko) 2009-04-22
NO20071504L (no) 2007-05-25
PE20060504A1 (es) 2006-07-18
JP2008510765A (ja) 2008-04-10
EP1784399B1 (en) 2011-06-15
CN101006079A (zh) 2007-07-25
IL181386A0 (en) 2007-07-04
CA2575720C (en) 2012-10-02
EP1784399A2 (en) 2007-05-16
KR20070038567A (ko) 2007-04-10
US20080293708A1 (en) 2008-11-27
PL1784399T3 (pl) 2011-11-30
ES2366038T3 (es) 2011-10-14
TW200621728A (en) 2006-07-01
JP4674236B2 (ja) 2011-04-20
TNSN07074A1 (en) 2008-06-02
CA2575720A1 (en) 2006-03-02
MA28813B1 (fr) 2007-08-01
GT200500229A (es) 2006-03-29
PT1784399E (pt) 2011-08-26
ATE512960T1 (de) 2011-07-15
RU2395507C2 (ru) 2010-07-27
US7910585B2 (en) 2011-03-22
AR050536A1 (es) 2006-11-01

Similar Documents

Publication Publication Date Title
BRPI0514731A (pt) derivados de pirimidina
BRPI0514681A (pt) derivados de pirimidina
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
UY30057A1 (es) Pirimidinas sustituidas con sulfoximinas, procesos para su producción y uso de las mismas como fármacos
BRPI0513901A (pt) derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
ECSP099044A (es) Compuestos de pirimido fusionados
BRPI0707704A8 (pt) derivados de antranilamida / 2-amino-heteroareno carboxamida
JO2734B1 (en) Organic compounds
TW200732323A (en) Organic compounds
DOP2011000176A (es) Compuestos organicos
TW200611904A (en) Aza-bicyclononanes
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
UY30881A1 (es) Derivados de fenotiazina, procedimientos y su uso como productos farmacéuticos
ATE445593T1 (de) Acetylenderivate
JO2770B1 (en) Organic compounds
GB0508318D0 (en) Organic compounds
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
BRPI0512677A2 (pt) derivados de quinazolina
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
ATE481972T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
DE602006016430D1 (de) Phosphodiesteraseinhibitoren auf azolbasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.